Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-04

Study Completion Date

2020-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the safety and efficacy of hydrocortisone eye drops in the treatment of OSD (ocular surface disease) patients with and without glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ocular Pressure in Steroid-treated Dermatology Patients

NCT01759914

Topical Corticosteroid-treated Dermatology Patients Intra-ocular Pressure

TERMINATED

SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients

NCT07152132

Glaucoma, Open Angle

RECRUITING NA

Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma

NCT02338362

Ocular Hypertension Glaucoma, Open-Angle

COMPLETED PHASE4

Management Steroid Induced Glaucoma

NCT04673201

Steroid-Induced Glaucoma

UNKNOWN NA

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772

Glaucoma Ocular Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ocular surface comprises the cornea, conjunctiva, eyelids and lacrimal glands and any disorder in these structures can be classified as an ocular surface disorder (OSD). OSD includes Dry Eye Disease (DED), blepharitis and meibomian gland dysfunction (MDG), allergic eye diseases (AED), chemical and thermal burns; all these conditions can severely affect eyesight and quality of life, and sometime even blindness. Patients with OSD can develop photophobia, corneal scarring, intermittent blurred vision, pain, limited ability to perform daily activities, reduced vitality, poor general health and, in many cases, depression.

Glaucoma, one of the leading causes of irreversible blindness, is an optic neuropathy characterized by thinning of retinal nerve fiber layer and increase of optic disc cupping , whose main risk factor is closely related to the intraocular pressure (IOP) levels. Thus, the management of the disease consists in the lowering IOP through medical, laser or surgical therapy . However, IOP reduction is most commonly achieved using topical ocular medications, which often contain preservatives employed to maintain stability and sterility of the product. Preservatives can be associated with undesirable adverse effects such as allergy, local irritation and inflammation . The long-term use of anti-glaucoma medications produces several alterations of ocular surface components, especially at the conjunctival level where epithelial modifications, dendritic cell activation, conjunctiva-associated lymphoid tissue activation, and goblet cell (GCs) loss easily occur GCs play crucial tasks in the homeostasis of the ocular surface being the main source of mucoproteins, essential to maintain tear film stability. Thus, the loss of GCs progressively leads to the happening of an iatrogenic OSD . Moreover, advancing age is a significant risk factor for both OSD and glaucoma, further complicated by treatments for each condition, which can interact among them and yield counterproductive effects . For these reason glaucoma is often associated with OSD .Ocular surface inflammation is crucial in the pathophysiology of OSD, therefore anti-inflammatory therapy, including corticosteroids, may be of benefit to OSD patients . However, in susceptible individuals steroid-induced glaucoma or ocular hypertension can occur after steroid use. Individuals who develop an increase in IOP following steroid use are referred to as "steroid responders" . In a recent study Kallab et al. have found that dry eye treatment with low hydrocortisone dose reduced ocular inﬂammation without inducing increases in IOP ; glaucomatous patients were excluded from this study. Herein we evaluate the safety and efficacy of hydrocortisone eye drops in the treatment of OSD patients with and without glaucoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Surface Disease Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: glaucoma

OSD patients with glaucoma

Group Type EXPERIMENTAL

Hydrocortisone (CORTIVIS ®)

Intervention Type DRUG

Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.

Group B: no glaucoma

OSD patients without glaucoma

Group Type ACTIVE_COMPARATOR

Hydrocortisone (CORTIVIS ®)

Intervention Type DRUG

Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocortisone (CORTIVIS ®)

Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age of at least 18 years
* diagnosis of OSD (Ocular Surface Disease)
* normal ophthalmic ﬁndings except history of OSD for at least 3 months, and current therapy with topical lubricants for at least 3 months
* POAG (primary open-angle glaucoma ) patients on medical therapy

Exclusion Criteria

* clinically signiﬁcant slit lamp ﬁndings at screening visit except OSD
* participation in a clinical trial in the 4 weeks preceding the screening visit
* symptoms of a clinically relevant illness in the 3 weeks before the screening visit
* presence/ history of a severe medical or surgical condition
* intake of parasympathomimetic or antipsychotic drugs
* wearing of contact lenses
* previous refractive laser surgery (e.g photorefractive keratectomy-PRK, laser assisted in situ keratomileusis-LASIK, etc.)
* history of IOP increase caused by systemic or topical treatment with corticosteroids
* IOP greater than 22 mmHg
* treatment with corticosteroids in the 4 weeks preceding the study
* types of glaucoma other than POAG
* ocular infection or clinically signiﬁcant inﬂammation
* ocular surgery in the 3 months preceding the study
* Sjögren's syndrome, Stevens-Johnson syndrome
* history of allergic conjunctivitis
* pregnancy, planned pregnancy or lactating
* known hypersensitivity to any component of study medication

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes